Vecuronium Bromide

Inquiry

Cat Number

API50700726

CAS Number

50700-72-6

For research use only. We do not supply to patients.

For pharmaceutical-grade products or other inquiries, please contact our experts.

Product Detail Description Scientific Support Customer Q&A

CAS Number

50700-72-6

EINECS

256-723-9

Storage

Under -20℃

Synonyms

[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetoxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-(1-piperidyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]acetate

Molecular Formula

C34H57BrN2O4

Molecular Weight

637.7

Smiles

CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-]

Appearance

White solid

Standard

USDMF/WC

General Description

Vecuronium Bromide is a non-depolarizing neuromuscular blocking agent of the monoquaternary aminosteroid class. It lacks cardiovascular side effects due to minimal vagolytic or ganglionic blocking activity at clinical doses.

Mechanism of Action

Vecuronium Bromide competitively antagonizes nicotinic acetylcholine receptors at the postsynaptic membrane of the neuromuscular junction, preventing acetylcholine binding and blocking depolarization-induced skeletal muscle contraction.

Application

Used as an adjunct in surgical anesthesia and intensive care. Vecuronium Bromide is indicated for muscle relaxation during surgery, endotracheal intubation, and mechanical ventilation support.

Vecuronium Bromide is a non-depolarizing, intermediate-acting neuromuscular blocking agent used as an adjunct to general anesthesia for endotracheal intubation and skeletal muscle relaxation during surgery. It acts by competitively binding to cholinergic receptors at the motor endplate, blocking neuromuscular transmission, which is reversible by acetylcholinesterase inhibitors. Compared to pancuronium, vecuronium is approximately 1.3 times more potent but has a shorter duration of action. A key advantage is its lack of significant cardiovascular effects—it does not cause tachycardia or blood pressure changes at clinical doses, making it suitable for patients with ischemic heart disease. Histamine release is minimal, and allergic reactions are rare. The standard intubating dose is 0.08–0.1 mg/kg IV, with onset within 1 minute, good intubating conditions at 2.5–3 minutes, and clinical duration of 25–40 minutes. Maintenance doses of 0.01–0.015 mg/kg show no cumulative effect.

Fig. 1 The effects of Vecuronium on heart rate at rat atrial tissue. (Gursoy S.; et al. 2011)

References

Gursoy S, et al. Investigation of the cardiac effects of pancuronium, rocuronium, vecuronium, and mivacurium on the isolated rat atrium. Current therapeutic research, 2011, 72(5): 195-203.

What distinguishes Vecuronium Bromide from other aminosteroid neuromuscular blockers?

Vecuronium Bromide exhibits minimal histamine release and lacks significant cardiovascular effects compared to pancuronium, offering a more stable hemodynamic profile.

What storage conditions are required?

Store under -20℃ in a tightly sealed container, protected from light and moisture.

What purity grade is available?

It is supplied as a high-purity grade suitable for R&D and pharmaceutical manufacturing.

Can packaging and order quantities be customized?

Yes, both packaging formats and order quantities can be tailored to meet specific R&D and production needs.